Drugs affecting biliary composition and flow

Go to algorithm

exp date isn't null, but text field is

URSODEOXYCHOLIC ACID

Therapy notes

Formulation and dosage details

Formulation:

Tablets 250mg

Dosage:

Primary biliary cirrhosis: 10 to 15mg/kg daily in 2 to 4 divided doses. Tolerance can vary between individual brands; if necessary consider brand name prescribing.

Formulation and dosage details

Formulation:

Capsules 250mg

Dosage:

Primary biliary cirrhosis: 10 to 15mg/kg daily in 2 to 4 divided doses. Tolerance can vary between individual brands; if necessary consider brand name prescribing.

OBETICHOLIC ACID

Therapy notes

MHRA advice: Obeticholic Acid (Ocaliva): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring (April 2018)

Formulation and dosage details

Formulation:

Tablets (Ocaliva®) 5mg, 10mg

Dosage:

Primary biliary cirrhosis/cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid as per SMC2132/17.